NCT01498419View on ClinicalTrials.gov

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

July 31, 2013

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

Moxifloxacin (M)

DRUG

Pretomid (Pa)

DRUG

Pyrazinamide (Z)

DRUG

Rifafour

Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets

Trial Locations (8)

1736

The Aurum Institute: Tembisa Hospital, Tembisa

2570

Klerksdorp Tshepong Hospital, Klerksdorp

4013

KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban

7531

Task Applied Science, Karl Bremer Hospital, Cape Town

7700

University of Cape Town Lung Institute (Pty) Ltd, Cape Town

Unknown

CHRU Themba Lethu Clinic, Johannesburg

Ifakara Health Institute, Bagamoyo

Mbeya Medical Research Programme, Mbeya

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT01498419 - Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) | Biotech Hunter | Biotech Hunter